BioPharmSignal logoBioPharmSignal

Biotech News

Innate Pharma Announces Proposed Offering of Ordinary Shares

Innate Pharma (IPHA)Innate PharmaFinancing

The following pages contain information regarding the share capital increase through a private placement of Innate Pharma. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.

Enter your country of residence

Access to this information is restricted to persons that are located outside of France

Related news

IPHAInnate Pharma2026-08-13 07:14 EST

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

IPHAInnate Pharma2026-07-20 14:53 EST

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ELVNEnliven Therapeutics2026-06-11 20:05 EST

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

ZNTLZentalis2026-08-13 20:01 EST

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

View all latest news

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

IPHAInnate Pharma2026-08-13 07:14 EST

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

IPHAInnate Pharma2026-08-10 14:02 EST

Innate Pharma Announces Proposed Offering of Ordinary Shares

IPHAInnate Pharma2026-08-09 21:32 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close
2.26 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States